2. Immunology/Inflammation
  3. CD20
  4. Ofatumumab

Ofatumumab  (Synonyms: 奥法木单抗)

目录号: HY-P9961 纯度: 99.00%
COA 技术支持

Ofatumumab 是一种全人源的抗 CD20 单克隆抗体，在表达 CD20 的 B 淋巴细胞中诱导抗体依赖性细胞介导的细胞毒性 (ADCC) 和补体依赖性细胞毒性 (CDC)。Ofatumumab 对 CD20 阳性 B 淋巴细胞具有强裂解活性，并通过 ADCC 和 CDC 清除 CD20 阳性肿瘤细胞。Ofatumumab 尤其对低表达 CD20 的耐药细胞仍有效，可应用于慢性淋巴细胞白血病 (CLL) 领域的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CAS No. : 679818-59-8

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg ￥4200
In-stock
5 mg ￥7100
In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Ofatumumab 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL)[1][2][3].

同型

Human IgG1 kappa
推荐同型对照抗体
种属

Human
IC50 & Target

CD20/MS4A1
体外研究
(In Vitro)

Ofatumumab (10 μg/mL；6 h) 在套细胞淋巴瘤 (MCL) 细胞系的补体依赖细胞毒性 (CDC) 实验中，诱导细胞裂解，效果优于 Rituximab (HY-P9913)，且对低 CD20 表达或高补体抑制蛋白 (CD55/CD59) 表达的耐药细胞仍具活性[1]。
Ofatumumab (10 μg/mL；24-72 h) 的 B 细胞淋巴瘤细胞系具有直接杀伤作用，与 Rituximab 的抑制作用相似[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Ofatumumab 相关抗体:

Cell Cytotoxicity Assay[1]

Cell Line: Mantle cell lymphoma (MCL) cell lines (Granta, HBL-2, Jeko-1, Mino, Rec-1, Z-138)
Concentration: 10 μg/mL
Incubation Time: 6 h
Result: Cell Lysis : Induced higher CDC-mediated lysis compared to rituximab in all tested cell lines except Granta, with significant differences in Mino, Rec-1, and Jeko-1 cells. For example, in Mino cells, achieved 65% lysis vs. 35% with rituximab.
Resistance Mechanisms : Cells with high CD55/CD59 expression (e.g., Raji-4RH) showed reduced rituximab-induced lysis, but Ofatumumab maintained efficacy, indicating less dependency on CD20 density.

Cell Viability Assay[1]

Cell Line: B-cell lymphoma cell lines (Mino, Rec-1, HBL-2, Raji, RL)
Concentration: 10 μg/mL
Incubation Time: 24, 48, 72 h
Result: Cell Viability : Both antibodies caused time-dependent viability reduction, with Ofatumumab showing comparable activity to rituximab across most cell lines.
A significant difference was observed in Mino cells at 72 h, where Ofatumumab reduced viability to 30% vs. 45% with Rituximab.
Direct Cytotoxicity : Flow cytometry and immunofluorescence revealed no significant differences in apoptosis or cell cycle arrest between the two antibodies, suggesting minimal direct cytotoxic effects beyond immune-mediated lysis.
体内研究
(In Vivo)

Ofatumumab (10 mg/kg；静脉注射；第 0、3、7、10 天；共 4 次) 在 SCID 小鼠 Z-138 细胞皮下移植瘤模型中，显著延缓肿瘤生长，延长小鼠生存时间，效果优于 Rituximab (HY-P9913) (10 mg/kg)[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female SCID mice (6-8 weeks old, ~20 g) + subcutaneous xenograft model of human mantle cell lymphoma (Z-138 cells)[1]
Dosage: 10 mg/kg (dissolved in sterile saline)
Administration: Intravenous injection via tail vein; 4 doses on days 0, 3, 7, and 10 post-tumor engraftment
Result: Significantly delayed early tumor progression compared to rituximab. Tumor volume in the ofatumumab group remained smaller than 500 mm3 for over 80 days, whereas the rituximab group showed progressive growth exceeding 2000 mm3 by day 120.
Resulted a median survival time of >90 days in the ofatumumab group (median not reached by study end), compared to 127 days in the Rituximab group.
Reduced tumor cellularity and increased apoptotic cells in of Atumumab-treated mice, with no evidence of treatment-related organ toxicity.
Clinical Trial
基因 ID

931  [NCBI]

Accession
应用

ELISA, FACS, Functional assay
偶联物

Unconjugated
复溶方法

The product can be reconstituted/diluted with sterile PBS or saline.
分子量

145.94 kDa

CAS 号
性状

液体

颜色

Colorless to light yellow

中文名称

奥法木单抗； 奥法妥木单抗
运输条件

Shipping with dry ice.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Biological Activity
  • Ofatumumab has a significant ADCP effect on Raji cells in a dose-dependent manner.The EC50 for this effect is 24.00 and 25.15 ng/mL.
纯度 & 产品资料

纯度: 99.00%

COA (265 KB)

抗体抑制剂使用指南 (1152 KB)
参考文献

Ofatumumab 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ofatumumab679818-59-8奥法木单抗 奥法妥木单抗CD20anti-CD20 monoclonal antibodyselectivecytotoxicitylysing B cellschronic lymphocytic leukaemiaInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Ofatumumab
目录号：
HY-P9961
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z